To include your compound in the COVID-19 Resource Center, submit it here.

Skyrizi launch beats expectations again as AbbVie looks to post-Humira future

Recently launched psoriasis drug Skyrizi exceeded sales expectations for the second quarter in a row, as immunology and hemato-oncology drugs continue to drive AbbVie’s growth ahead of anticipated U.S. biosimilar competition for Humira.

Sales of Skyrizi risankizumab in 3Q19 were $91 million, beating the Street’s $86 million consensus. From its launch in May through Sept. 30, sales of the drug have

Read the full 603 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers